Angiogenesis as a therapeutic target in breast cancer

Title:Angiogenesis as a therapeutic target in breast cancer

Volume: 12 Issue: 12

Author(s): Angelos K. Koutras, Ioannis Starakis, Dionysia Lymperatou and Haralabos P. Kalofonos

Affiliation:

Keywords: Angiogenesis, bevacizumab, breast cancer, treatment.

Abstract: Current evidence indicates that angiogenesis plays an important role in the pathogenesis of several malignancies, including breast cancer. Bevacizumab is a monoclonal antibody that targets the vascular endothelial growth factor (VEGF). Recent clinical data have demonstrated that the addition of bevacizumab to first-line chemotherapy improves the progression-free survival of patients with advanced breast cancer. This review presents an update on the role of bevacizumab, as well as other anti-angiogenic agents in the management of patients with breast carcinoma.

Cite this article as:

K. Koutras Angelos, Starakis Ioannis, Lymperatou Dionysia and P. Kalofonos Haralabos, Angiogenesis as a therapeutic target in breast cancer, Mini-Reviews in Medicinal Chemistry 2012; 12 (12) . https://dx.doi.org/10.2174/138955712802761988